专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007056135A1 METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED 审中-公开
标题翻译：用SAHA和PEMETREXED治疗癌症的方法
公开(公告)号：WO2007056135A1
公开(公告)日：2007-05-18
申请号：PCT/US2006/042950
申请日：2006-11-03
申请人： MERCK & CO., INC. , PLUDA, James , FRANKEL, Stanley , RICHON, Victoria, M. , AVERBUCH, Steven , CHIAO, Judy
发明人： PLUDA, James , FRANKEL, Stanley , RICHON, Victoria, M. , AVERBUCH, Steven , CHIAO, Judy
IPC分类号： A61K31/517 , A61K31/519 , A61K31/52
CPC分类号： A61K31/167 , A61K31/19 , A61K31/4985 , A61K31/519 , A61K31/69 , A61K2300/00
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
摘要翻译：本发明涉及通过向有需要的受试者施用第一量的组蛋白脱乙酰酶（HDAC）抑制剂或其药学上可接受的盐或水合物来治疗有需要的受试者的癌症的方法和第二量的一种抗癌剂。 HDAC抑制剂和抗癌剂可以施用以包含治疗有效量。在各个方面，HDAC抑制剂和抗癌剂的作用可以是相加的或协同的。

2. 发明申请

WO2007056162A3 METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES 审中-公开
公开(公告)号：WO2007056162A3
公开(公告)日：2007-05-18
申请号：PCT/US2006/042991
申请日：2006-11-03
申请人： MERCK & CO., INC. , UNIVERSITY OF PITTSBURGH , CHIAO, Judy , PARADISE, Carolyn , FRANKEL, Stanley , RAMALINGAM, Suresh, Sakkarai , BELANI, Chandra
发明人： CHIAO, Judy , PARADISE, Carolyn , FRANKEL, Stanley , RAMALINGAM, Suresh, Sakkarai , BELANI, Chandra
IPC分类号： A61K31/282 , A61K31/16
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof an amount of a histone deacetylase (HDAC) inhibitor, e.g., suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and an amount of one or more anticancer agents such as Carboplatin or Paclitaxel. The HDAC inhibitor and the anticancer agents may be administered to comprise therapeutically effective amounts.

3. 发明申请

WO2008132443A1 USE OF SAPACITABINE TO TREAT PROLIFERATIVE DISEASE 审中-公开
标题翻译：使用SAPACITABINE治疗增殖性疾病
公开(公告)号：WO2008132443A1
公开(公告)日：2008-11-06
申请号：PCT/GB2008/001424
申请日：2008-04-24
申请人： CYCLACEL LIMITED , CHIAO, Judy
发明人： CHIAO, Judy
IPC分类号： A61K31/513 , A61P35/00
CPC分类号： A61K31/7068 , A61K31/513
摘要： One aspect of the present invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating a proliferative disorder, wherein the sapacitabine or metabolite thereof is administered in a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises administering a therapeutically effective amount of sapacitabine or metabolite thereof for about 2 to about 6 days per week, for 2 weeks out of 3 weeks. Another aspect of the invention relates to the use of sapacitabine, or a metabolite thereof, in the preparation of a medicament for treating cutaneous T-cell lymphoma (CTCL).
摘要翻译：本发明的一个方面涉及用于制备用于治疗增殖性病症的药物中的西他滨或其代谢物的用途，其中所述的沙美他滨或其代谢物以包含至少一个治疗周期的给药方案施用，其中所述治疗周期包括在3周内给予治疗有效量的每周约2至约6天的治疗有效量的沙美他滨或其代谢物2周。本发明的另一方面涉及用于制备用于治疗皮肤T细胞淋巴瘤（CTCL）的药物的西他滨或其代谢物的用途。

4. 发明申请

WO2012140436A1 DOSAGE REGIMEN FOR SAPACITABINE AND DECITABINE IN COMBINATION FOR TREATING ACUTE MYELOID LEUKEMIA 审中-公开
标题翻译：用于治疗急性髓性白血病的组合中的SAPACITABINE和组合的剂量
公开(公告)号：WO2012140436A1
公开(公告)日：2012-10-18
申请号：PCT/GB2012/050815
申请日：2012-04-13
申请人： CYCLACEL LIMITED , CHIAO, Judy
发明人： CHIAO, Judy
IPC分类号： A61K31/706 , A61K31/7068 , A61P35/02
CPC分类号： A61K31/7068 , A61K31/706 , A61K2300/00
摘要： A first aspect of the invention relates to a method of treating AML in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment- related toxicities are resolved, whichever is longer.
摘要翻译：本发明的第一方面涉及一种在受试者中治疗AML的方法，所述方法包括向受试者施用治疗有效量的（i）西他滨或其代谢物; 和（ii）地西他滨; 根据包含至少一个第一治疗周期和至少一个第二治疗周期的给药方案，其中所述第一治疗周期包括施用治疗有效量的地西他滨连续5至10天，随后休息期为3至5 周，或直到治疗相关毒性得到解决，以较长者为准; 并且其中所述第二治疗周期包括每周连续3天施用治疗有效量的沙美他滨或其代谢物2周，然后2至4周的休息期，或直到治疗相关毒性被解决，以较长者为准。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式